Next Investors logo grey

MGC Pharma scores GMP licence: kicks off commercial-scale production


Published 13-JUL-2018 10:20 A.M.


2 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.

Click Here to View Latest Articles

Diversified ASX pot-stock, MGC Pharmaceuticals (ASX:MXC), has now secured full Good Manufacturing Practice (GMP) certification for its European production and compounding facility – the final step towards kicking off a commercial-scale production operation.

This is a pivotal milestone for the $88 million-capped biotech growth story. GMP certification means that MXC is now fully licenced to manufacture cannabis-based medicine containing both THC (tetrahydrocannabinol) and CBD (cannabidiol) active pharmaceutical ingredients (APIs).

This also puts MXC in a unique position as now one of the only companies with ‘seed-to-pharma’ capabilities, making its Slovenian production facility one the most advanced of its kind within Europe.

Following the completion of all criteria in the production process of pharmaceutical-grade cannabis, this licence signifies MXC’s compliance with Europe’s strict quality standards for production, manufacturing and handling of pharmaceutical-grade, pot-based products.

MXC can now begin production of pharma-grade medicinal cannabis products, beginning with a full-scale manufacturing operation of CannEpilTM — its first medicinal cannabis treatment for drug-resistant or refractory epilepsy.

Final tests on the first batch CannEpil have been completed, and the drug will go through final independent validation by Slovenia’s National Institute of Chemistry before being provided to patients in both Slovenia and Australia.

The first batch is expected to be completed in the third quarter of the year, with exportation into Australasia beginning shortly thereafter.

As always, it should be noted that MXC is an early stage play and anything can happen, so seek professional financial advice if considering this stock for your portfolio.

MXC will also produce cannabinoid-based IMPs (Investigational Medicinal Products) for use across the entire MGC clinical studies and research pipelines.

Next Investors ImageNext Investors Image

MGC Pharmaceuticals co-founder and managing director, Romy Zomer, commented: “We are delighted to have finally completed the inspection procedures — this is one more step in our ‘seed-to-pharma’ agenda as a leading bio-pharma company with formulated medicines in the global market.”

General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.